Pregabalin for Persistent Tremor in Parkinson's Disease
Pregabalin should NOT be used to treat persistent tremor in Parkinson's disease patients already on carbidopa-levodopa. The evidence shows pregabalin is ineffective for parkinsonian tremor and may actually worsen symptoms or induce parkinsonism itself.
Why Pregabalin Is Not Recommended
Pregabalin has demonstrated no efficacy for essential tremor in controlled trials, and there is no evidence supporting its use for parkinsonian tremor. A 2009 randomized, double-blind, placebo-controlled crossover trial found no improvement in any tremor rating scale measures with pregabalin (150-600 mg/day), and quality of life scores actually worsened significantly during treatment. 1
A 2025 meta-analysis of gabapentinoids (including pregabalin) for essential tremor confirmed that pregabalin specifically showed no significant reduction in tremor severity from baseline, unlike gabapentin which showed some within-group benefit. This suggests pregabalin lacks even the modest tremor-suppressing properties seen with its related compound. 2
Pregabalin can paradoxically induce or worsen parkinsonism. Case reports document pregabalin-induced parkinsonism with resting tremors, bradykinesia, and movement difficulties that resolved completely upon drug discontinuation. 3 This makes it particularly inappropriate for patients who already have Parkinson's disease.
Common adverse effects of pregabalin—drowsiness and dizziness—overlap with existing challenges in PD patients and would compound functional impairment. 1
What TO Do for Persistent Tremor in PD
First-Line Optimization
Optimize the carbidopa-levodopa regimen first. Levodopa remains the most efficacious drug for PD tremor and should be the primary approach for troublesome tremor. 4
Consider switching from immediate-release to extended-release or combination formulations (e.g., Rytary) if tremor control is inadequate with standard dosing. Extended-release formulations provide 4-6 hours of symptom relief versus 2-3 hours with immediate-release, which may better control fluctuating tremor. 5
Ensure adequate carbidopa dosing (70-100 mg/day minimum) to prevent peripheral side effects that might limit levodopa dose escalation. 6
Adjunctive Pharmacologic Options
Propranolol may be added as an adjunct for both resting and action tremor when levodopa response is insufficient. 4
Anticholinergics have demonstrated antitremor efficacy but should be reserved for young, cognitively intact patients due to their adverse effect profile (confusion, memory impairment, urinary retention). 4
Clozapine may be considered for refractory tremor despite its unfavorable adverse effect profile requiring regular blood monitoring. 4
Advanced Therapies for Refractory Tremor
For drug-refractory PD tremor despite levodopa optimization, deep brain stimulation (DBS) and focused ultrasound are first-line considerations. Subthalamic nucleus DBS yields large improvements in motor symptoms including tremor, with benefits persisting beyond 15 years. 7
DBS can be highly effective even in selected patients without motor fluctuations when tremor is medication-refractory. 4
Early referral for advanced-therapy evaluation is recommended once oral therapy has been optimized, rather than waiting for severe disability. 7
Common Pitfalls to Avoid
Do not extrapolate essential tremor treatments to parkinsonian tremor. The pathophysiology differs, and medications like pregabalin that might theoretically help essential tremor have no evidence in PD tremor. 4
Avoid adding pregabalin or other unproven agents before fully optimizing levodopa dosing and formulation. 6, 4
Do not overlook "off-period" tremor that may respond to treating motor fluctuations with MAO-B inhibitors, COMT inhibitors, or continuous infusions rather than adding tremor-specific agents. 4